Welcome to our dedicated page for Navidea Biopharm news (Ticker: NAVB), a resource for investors and traders seeking the latest updates and insights on Navidea Biopharm stock.
Navidea Biopharmaceuticals, Inc. (NAVB) is a biopharmaceutical company that describes its focus as the development of precision immunodiagnostic agents and immunotherapeutics built on its proprietary Manocept platform. Company news frequently highlights developments related to this platform, including clinical research involving Tc99m tilmanocept, which Navidea identifies as the first product developed and commercialized from Manocept.
News releases from Navidea cover a range of topics that are relevant to investors, creditors, and other stakeholders. These include updates on clinical programs, such as exploratory analyses in rheumatoid arthritis trials using Tc99m tilmanocept imaging, as well as shifts in focus toward therapeutic assets. Corporate strategy communications often reference the company’s Fix, Fund, Propel framework, which Navidea links to operational changes, financing activities, and efforts to advance its technology toward potential market applications.
Navidea’s news flow also includes significant corporate and capital structure events. Examples disclosed by the company include the NYSE American’s decision to suspend trading and initiate delisting proceedings for its common stock, the transition to trading on over-the-counter markets, the adoption and extension of a Section 382 Rights Plan aimed at protecting tax attributes, and the filing of Form 15 to deregister its securities and suspend SEC reporting obligations.
More recently, Navidea announced that it filed a voluntary petition for relief under Chapter 11, Subchapter V of the U.S. Bankruptcy Code, stating that the process is intended to support an orderly restructuring of its financial obligations while continuing limited operations. Visitors to this news page can review these types of announcements to understand how Navidea describes its business focus, technology platform, strategic framework, and material corporate events over time.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) announced its participation in the 2021 ICR Conference on January 14, 2021, at 2:30 p.m. EST. The conference will feature CEO Jed Latkin and CBO Joel Kaufman. A live video webcast of the presentation will be available, and a replay will be accessible for one year. Navidea focuses on developing precision immunodiagnostic agents via its Manocept™ platform, designed to enhance patient care and improve diagnostic accuracy. For more information, visit www.navidea.com.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) announced the appointment of Malcolm G. Witter to its Board of Directors. With decades of experience in financial and corporate governance, Witter currently leads corporate development at USI Insurance Services. He has held positions at Bear Stearns, EF Hutton, and Dean Witter, and earned his MBA from Stanford. CEO Jed Latkin expressed confidence in Witter's expertise in M&A and corporate finance to help guide the company in its future developments.
Navidea Biopharmaceuticals (NYSE American: NAVB) announced the full enrollment of its NAV3-31 Phase 2B study, evaluating Tc99m tilmanocept imaging for rheumatoid arthritis (RA) patients. The three-arm trial includes healthy subjects and RA patients, assessing treatment efficacy indicators. Interim results support the imaging's predictive capabilities. The company plans to finalize the Phase 3 study design with the FDA while maintaining trial momentum. RA affects over 1.3 million Americans, and successful product development could significantly impact patient management.